The Experts below are selected from a list of 474 Experts worldwide ranked by ideXlab platform
Tanweer A. Syed - One of the best experts on this subject based on the ideXlab platform.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot). Design and Setting: This was a placebo-controlled, double-blind study. Patients and Participants: 60 men aged between 18 and 60 years (mean 35.4 years) with a mean duration of disease of 28.4 weeks, positive mycology and culture-confirmed tinea pedis participated in the study. Methods: The participants were sequentially randomised into three parallel groups (Butenafine cream, terbinafine cream and placebo). Each patient was given a precoded 25g tube and instructed to apply the trial medication to all tinea pedis lesions once daily at bedtime for 5 consecutive days per week (maximum of 2 weeks’ active treatment). Patients were examined on a weekly basis. Cure was defined as negative potassium hydroxide test results and negative fungal culture (mycological cure). Participants cured during the treatment were allowed to discontinue the treatment. Results: By the end of the treatment 60% of all patients were cured. Butenafine cured 18 (90%) patients at 1 week and no further patients at 2 weeks. Terbinafine cured no patients at 1 week and 16 (80%) patients at 2 weeks. Placebo cured no patients at 1 week and 2 (10%) patients at 2 weeks (p < 0.0001, Butenafine and terbinafine vs placebo at 2 weeks). None of the patients reported any drug-related adverse events and no patients discontinued treatment. Conclusion: Butenafine 1% in cream is well tolerated and comparatively better than terbinafine 1% in cream or placebo to cure plantar or moccasin-type tinea pedis in men. Further clinical studies appear warranted.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Shahida M. Ali, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot). Design and Setting: This was a placebo-controlled, double-blind study. Patients and Participants: 60 men aged between 18 and 60 years (mean 35.4 years) with a mean duration of disease of 28.4 weeks, positive mycology and culture-confirmed tinea pedis participated in the study. Methods: The participants were sequentially randomised into three parallel groups (Butenafine cream, terbinafine cream and placebo). Each patient was given a precoded 25g tube and instructed to apply the trial medication to all tinea pedis lesions once daily at bedtime for 5 consecutive days per week (maximum of 2 weeks’ active treatment). Patients were examined on a weekly basis. Cure was defined as negative potassium hydroxide test results and negative fungal culture (mycological cure). Participants cured during the treatment were allowed to discontinue the treatment. Results: By the end of the treatment 60% of all patients were cured. Butenafine cured 18 (90%) patients at 1 week and no further patients at 2 weeks. Terbinafine cured no patients at 1 week and 16 (80%) patients at 2 weeks. Placebo cured no patients at 1 week and 2 (10%) patients at 2 weeks (p < 0.0001, Butenafine and terbinafine vs placebo at 2 weeks). None of the patients reported any drug-related adverse events and no patients discontinued treatment. Conclusion: Butenafine 1% in cream is well tolerated and comparatively better than terbinafine 1% in cream or placebo to cure plantar or moccasin-type tinea pedis in men. Further clinical studies appear warranted.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot).
-
Butenafine hydrochloride: for the treatment of interdigital tinea pedis.
Expert Opinion on Pharmacotherapy, 2000Co-Authors: Tanweer A. Syed, Howard I. MaibachAbstract:Butenafine, a derivative of benzylamine with potent fungicidal activity is a new generation of antimycotic compound that has shown to be extremely effective against experimentally-induced tinea pedis in the guinea-pig, a situation that resembles synergetic pathology similar to that of tinea pedis in humans. Butenafine, (N-4-tert-butylbenzyl-N-methyl-1-naphthalenemethyl-amine hydrochloride) with a chemical structure and mode of action similar to those of the allylamines, demonstrates superior fungicidal activity in vitro against dermatophytes and superior fungistatic activity toward Candida albicans than that of naftifine and terbinafine. In vitro, pharmacodynamic data has shown that the geometric mean of minimum inhibitory concentration values for Butenafine were comparatively lower than those of naftifine and clotrimazole against clinical isolates for many dermatophytes. It inhibits sterol synthesis by blocking the squalene epoxidation stage in fungi. In phramacokinetic assessments Butenafine achieves an...
-
management of toenail onychomycosis with 2 Butenafine and 20 urea cream a placebo controlled double blind study
Journal of Dermatology, 1998Co-Authors: Tanweer A. Syed, Seyed Ali Ahmad, Oliver Abbas Ahmadpour, Sadaf ShamsiAbstract:Onychomycosis is an increasingly common and recalcitrant fungal nail infection world-wide. The purpose of this placebo-controlled, double-blind study was to determine the clinical efficacy, chemical avulsion, and tolerability of 2% Butenafine hydrochloride and 20% urea incorporated in a cream to cure toenail onychomycosis in a preselected population. Sixty patients (38M, 22F), ranging between 18 and 60 years (mean 27.4), with more than 25% involvement of the big toenail were enrolled in the study. The diagnosis of onychomycosis was established by mycologic identification and reconfirmed by positive fungal culture. A precoded 25-g tube was randomly assigned to each patient (50 active and 10 placebo) with instructions to apply the trial medication to their infected toenail twice daily with an occlusive dressing for one week. The affected nail was removed with a nail clipper. No occlusive dressing was maintained after the initial one week regimen. To assess the chemical avulsion of the infected toenail, mycologic cure, clinical effectiveness of the treatment, and overall success, patients were examined twice a week for 16 weeks and thereafter on a weekly basis for a further 36 weeks. The treatment was well tolerated by all the patients throughout the study, with no dropouts. Marked improvement was seen in 73.3% patients after weeks 8, 16 and 24 with clinically and mycologically confirmed negative fungal culture. Code disclosure revealed that active Butenafine and urea cream cured significantly more patients than placebo (88% versus 0%; p < 0.0001). Of the 60 patients 91.6% reported no drug-related adverse symptoms. Five patients reported non-objective mild inflammation without discontinuation of the treatment. During one year follow-up of the study phase, none of the cured patients had a relapse. In conclusion, the mycologic and overall assessment of this study demonstrate that 2% Butenafine HCl and 20% urea incorporated in a cream for keratinolysis is safe to use and significantly more effective than placebo in curing big toenail onychomycosis.
Boni E. Elewski - One of the best experts on this subject based on the ideXlab platform.
-
Topley and Wilson's Microbiology and Microbial Infections - Management of Superficial Infections
Topley and Wilson's Microbiology and Microbial Infections, 2010Co-Authors: Jeff Weeks, Boni E. ElewskiAbstract:1 Antifungal Agents 2 Therapy of Selected Superficial Infections 3 Conclusion Keywords: management of superficial infections; multiple topical and systemic antimycotics-effective in superficial fungal infection management; allylamines/Butenafine-topical naftifine and topical/oral terbinafine; miscellaneous antimycotic agents; topical antifungal agents-as sole therapy in superficial fungal infections; therapy of selected superficial infections; tinea pedis and manuum; oropharyngeal candidiasis (thrush)
-
Treatment of interdigital tinea pedis with a 4-week once-daily regimen of Butenafine hydrochloride 1% cream : Update on Topical therapy for superficial fungal infections : Focus on Butenafine
Journal of The American Academy of Dermatology, 1997Co-Authors: Eduardo Tschen, Boni E. Elewski, David C. Gorsulowsky, David M. PariserAbstract:Background: Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American Butenafine clinical trials. Objective: We evaluated Butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial. Methods: Of 80 patients with positive fungal cultures, 40 applied Butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after. Results: Significantly more patients using Butenafine than using vehicle had mycologic cure (Butenafine, 88%; vehicle, 33%) and effective clinical response (Butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest (p
-
Treatment of interdigital tinea pedis with a 4-week once-daily regimen of Butenafine hydrochloride 1% cream.
Journal of the American Academy of Dermatology, 1997Co-Authors: Eduardo Tschen, Boni E. Elewski, David C. Gorsulowsky, David M. PariserAbstract:Abstract Background: Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American Butenafine clinical trials. Objective: We evaluated Butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial. Methods: Of 80 patients with positive fungal cultures, 40 applied Butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after. Results: Significantly more patients using Butenafine than using vehicle had mycologic cure (Butenafine, 88%; vehicle, 33%) and effective clinical response (Butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest ( p Conclusion: Butenafine applied once daily for 4 weeks resulted in an effective clinical response and mycologic cure of tinea pedis during treatment. Patients continued to improve for at least 4 weeks after treatment. (J Am Acad Dermatol 1997;36:S9-14.)
-
treatment of interdigital tinea pedis with a 4 week once daily regimen of Butenafine hydrochloride 1 cream update on topical therapy for superficial fungal infections focus on Butenafine
Journal of The American Academy of Dermatology, 1997Co-Authors: Eduardo Tschen, Boni E. Elewski, David C. Gorsulowsky, David M. PariserAbstract:Background: Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American Butenafine clinical trials. Objective: We evaluated Butenafine in the treatment of tinea pedis in a controlled, randomized, double-blind trial. Methods: Of 80 patients with positive fungal cultures, 40 applied Butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after. Results: Significantly more patients using Butenafine than using vehicle had mycologic cure (Butenafine, 88%; vehicle, 33%) and effective clinical response (Butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest (p<0.001) 4 weeks after treatment. Conclusion: Butenafine applied once daily for 4 weeks resulted in an effective clinical response and mycologic cure of tinea pedis during treatment. Patients continued to improve for at least 4 weeks after treatment.
-
One-week therapy with twice-daily Butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial.
Journal of the American Academy of Dermatology, 1997Co-Authors: R Savin, Daniel Stewart, Boni E. Elewski, R L De Villez, S Hong, T Jones, N Lowe, A Lucky, B Reyes, I WillisAbstract:Butenafine hydrochloride, a benzylamine derivative with potent antifungal activity, has been used in Japan to treat superficial fungal diseases. We evaluated the safety and efficacy of twice-daily Butenafine versus its vehicle in the treatment of interdigital tinea pedis in a multicenter, randomized, double-blind, parallel-group trial. A total of 402 patients with interdigital tinea pedis and a positive potassium hydroxide examination were enrolled. Of the 271 patients who had culture-confirmed tinea pedis and were assessed for efficacy, 132 applied Butenafine and 139 applied vehicle twice daily for 1 week. Patients were assessed for mycologic cure, effective treatment, overall cure, and mycologic/clinical cure. The rates of all four end points were significantly higher with Butenafine than with vehicle 5 weeks after treatment ended. Rates of mycologic cure and effective treatment with Butenafine were significantly higher than with vehicle at cessation of treatment. Adverse events to treatment occurred in less than 1% of patients treated with Butenafine and 2% of patients who applied vehicle. Butenafine applied twice daily for 1 week is highly effective in treating interdigital tinea pedis.
Seyed Ali Ahmad - One of the best experts on this subject based on the ideXlab platform.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot). Design and Setting: This was a placebo-controlled, double-blind study. Patients and Participants: 60 men aged between 18 and 60 years (mean 35.4 years) with a mean duration of disease of 28.4 weeks, positive mycology and culture-confirmed tinea pedis participated in the study. Methods: The participants were sequentially randomised into three parallel groups (Butenafine cream, terbinafine cream and placebo). Each patient was given a precoded 25g tube and instructed to apply the trial medication to all tinea pedis lesions once daily at bedtime for 5 consecutive days per week (maximum of 2 weeks’ active treatment). Patients were examined on a weekly basis. Cure was defined as negative potassium hydroxide test results and negative fungal culture (mycological cure). Participants cured during the treatment were allowed to discontinue the treatment. Results: By the end of the treatment 60% of all patients were cured. Butenafine cured 18 (90%) patients at 1 week and no further patients at 2 weeks. Terbinafine cured no patients at 1 week and 16 (80%) patients at 2 weeks. Placebo cured no patients at 1 week and 2 (10%) patients at 2 weeks (p < 0.0001, Butenafine and terbinafine vs placebo at 2 weeks). None of the patients reported any drug-related adverse events and no patients discontinued treatment. Conclusion: Butenafine 1% in cream is well tolerated and comparatively better than terbinafine 1% in cream or placebo to cure plantar or moccasin-type tinea pedis in men. Further clinical studies appear warranted.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Shahida M. Ali, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot). Design and Setting: This was a placebo-controlled, double-blind study. Patients and Participants: 60 men aged between 18 and 60 years (mean 35.4 years) with a mean duration of disease of 28.4 weeks, positive mycology and culture-confirmed tinea pedis participated in the study. Methods: The participants were sequentially randomised into three parallel groups (Butenafine cream, terbinafine cream and placebo). Each patient was given a precoded 25g tube and instructed to apply the trial medication to all tinea pedis lesions once daily at bedtime for 5 consecutive days per week (maximum of 2 weeks’ active treatment). Patients were examined on a weekly basis. Cure was defined as negative potassium hydroxide test results and negative fungal culture (mycological cure). Participants cured during the treatment were allowed to discontinue the treatment. Results: By the end of the treatment 60% of all patients were cured. Butenafine cured 18 (90%) patients at 1 week and no further patients at 2 weeks. Terbinafine cured no patients at 1 week and 16 (80%) patients at 2 weeks. Placebo cured no patients at 1 week and 2 (10%) patients at 2 weeks (p < 0.0001, Butenafine and terbinafine vs placebo at 2 weeks). None of the patients reported any drug-related adverse events and no patients discontinued treatment. Conclusion: Butenafine 1% in cream is well tolerated and comparatively better than terbinafine 1% in cream or placebo to cure plantar or moccasin-type tinea pedis in men. Further clinical studies appear warranted.
-
Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis
Clinical Drug Investigation, 2000Co-Authors: Tanweer A. Syed, Suhail M. Hadi, Zulfiqar A. Qureshi, Seyed Ali AhmadAbstract:Objective: To compare the clinical efficacy and tolerability of Butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot).
-
management of toenail onychomycosis with 2 Butenafine and 20 urea cream a placebo controlled double blind study
Journal of Dermatology, 1998Co-Authors: Tanweer A. Syed, Seyed Ali Ahmad, Oliver Abbas Ahmadpour, Sadaf ShamsiAbstract:Onychomycosis is an increasingly common and recalcitrant fungal nail infection world-wide. The purpose of this placebo-controlled, double-blind study was to determine the clinical efficacy, chemical avulsion, and tolerability of 2% Butenafine hydrochloride and 20% urea incorporated in a cream to cure toenail onychomycosis in a preselected population. Sixty patients (38M, 22F), ranging between 18 and 60 years (mean 27.4), with more than 25% involvement of the big toenail were enrolled in the study. The diagnosis of onychomycosis was established by mycologic identification and reconfirmed by positive fungal culture. A precoded 25-g tube was randomly assigned to each patient (50 active and 10 placebo) with instructions to apply the trial medication to their infected toenail twice daily with an occlusive dressing for one week. The affected nail was removed with a nail clipper. No occlusive dressing was maintained after the initial one week regimen. To assess the chemical avulsion of the infected toenail, mycologic cure, clinical effectiveness of the treatment, and overall success, patients were examined twice a week for 16 weeks and thereafter on a weekly basis for a further 36 weeks. The treatment was well tolerated by all the patients throughout the study, with no dropouts. Marked improvement was seen in 73.3% patients after weeks 8, 16 and 24 with clinically and mycologically confirmed negative fungal culture. Code disclosure revealed that active Butenafine and urea cream cured significantly more patients than placebo (88% versus 0%; p < 0.0001). Of the 60 patients 91.6% reported no drug-related adverse symptoms. Five patients reported non-objective mild inflammation without discontinuation of the treatment. During one year follow-up of the study phase, none of the cured patients had a relapse. In conclusion, the mycologic and overall assessment of this study demonstrate that 2% Butenafine HCl and 20% urea incorporated in a cream for keratinolysis is safe to use and significantly more effective than placebo in curing big toenail onychomycosis.
-
Management of Toenail Onychomycosis with 2% Butenafine and 20% Urea Cream: A Placebo‐controlled, Double‐blind Study
The Journal of Dermatology, 1998Co-Authors: Tanweer A. Syed, Seyed Ali Ahmad, Oliver Abbas Ahmadpour, Sadaf ShamsiAbstract:Onychomycosis is an increasingly common and recalcitrant fungal nail infection world-wide. The purpose of this placebo-controlled, double-blind study was to determine the clinical efficacy, chemical avulsion, and tolerability of 2% Butenafine hydrochloride and 20% urea incorporated in a cream to cure toenail onychomycosis in a preselected population. Sixty patients (38M, 22F), ranging between 18 and 60 years (mean 27.4), with more than 25% involvement of the big toenail were enrolled in the study. The diagnosis of onychomycosis was established by mycologic identification and reconfirmed by positive fungal culture. A precoded 25-g tube was randomly assigned to each patient (50 active and 10 placebo) with instructions to apply the trial medication to their infected toenail twice daily with an occlusive dressing for one week. The affected nail was removed with a nail clipper. No occlusive dressing was maintained after the initial one week regimen. To assess the chemical avulsion of the infected toenail, mycologic cure, clinical effectiveness of the treatment, and overall success, patients were examined twice a week for 16 weeks and thereafter on a weekly basis for a further 36 weeks. The treatment was well tolerated by all the patients throughout the study, with no dropouts. Marked improvement was seen in 73.3% patients after weeks 8, 16 and 24 with clinically and mycologically confirmed negative fungal culture. Code disclosure revealed that active Butenafine and urea cream cured significantly more patients than placebo (88% versus 0%; p < 0.0001). Of the 60 patients 91.6% reported no drug-related adverse symptoms. Five patients reported non-objective mild inflammation without discontinuation of the treatment. During one year follow-up of the study phase, none of the cured patients had a relapse. In conclusion, the mycologic and overall assessment of this study demonstrate that 2% Butenafine HCl and 20% urea incorporated in a cream for keratinolysis is safe to use and significantly more effective than placebo in curing big toenail onychomycosis.
Caroline M. Spencer - One of the best experts on this subject based on the ideXlab platform.
-
Butenafine
Drugs, 1998Co-Authors: Wendy Mcneely, Caroline M. SpencerAbstract:▴ Butenafine is a new antifungal agent with primary fungicidal activity against dermatophytes such as Trichophyton mentagrophytes , Microsporum canis and Trichophyton rubrum which cause tinea infections. ▴ ^14C-labelled Butenafine (≈30 μg/g tissue) was found within guinea-pig dorsal skin 24 hours after topical application. Most of the drag was distributed into the epidermis including the horny layer. Small amounts were found in the dermis, probably transported via sebaceous glands and hair follicles. ▴ In vitro , the minimum concentration that completely inhibited growth of dermatophytes (MIC) and the minimum fungicidal concentrations (MFC) for Butenafine against T. mentagrophytes and M. canis were similar (0.012 to 0.05 mg/L) and were 4 to 130 times lower than those for naftifine, tolnaftate, clotrimazole and bifonazole. It also has greater activity against T. rubrum, M. gypseum and Epidermophyton floccosum when compared with naftifine, tolnaftate and clotrimazole; comparisons with bifonazole against these strains were not available. ▴ Assessment after 1 week’s treatment in patients with tinea pedis revealed that mycological cure rates were greater in those who received twice-daily Butenafine for 1 week or once-daily Butenafine for 4 weeks than in placebo recipients. Mycological and overall cure rates were either further increased or maintained up to 5 weeks after treatment cessation compared with end-of-treatment values. ▴ In patients with tinea craris or tinea corporis who received once-daily Butenafine 1% for 2 weeks, the mycological and overall cure rates continued to increase for up to 4 weeks after treatment cessation.
Rosana Cé Bella Cruz - One of the best experts on this subject based on the ideXlab platform.
-
A case of Tinea nigra associated to a bite from a European rabbit (Oryctolagus cuniculus, Leporidae): the role of dermoscopy in diagnosis
Anais Brasileiros de Dermatologia, 2014Co-Authors: André Luiz Rossetto, Rosana Cé Bella Cruz, Patricia Rossetto Correa, Eduardo Figueiredo Pereira, Vidal Haddad Junior FilhoAbstract:We report a case of Tinea nigra in an adolescent living in Itapema, Santa Catarina, Brazil, who presented a hyperchromic macule on the palm of the left hand, close to another erythematous macule caused by a rabbit bite. The patient received guidance on accidents and animal bites and evolved well treated with topical Butenafine for the dermatomycosis. The authors also highlight the efficacy of the dermoscopic exam in diagnosing Tinea nigra with animal bite lesions and other traumas.
-
Images in Clinical Tropical Medicine Tinea nigra Presenting Speckled or "Salt and Pepper" Pattern
2014Co-Authors: Rosana Cé Bella Cruz, Vidal Haddad JuniorAbstract:A 7-year-old Caucasian female resident of the southern coast of Brazil presented dark spots on the left palm that converged to a unique macule with speckled pattern at about 1 month. The mycological exam and the fungi culture were typical of Hortaea werneckii, the agent of the superficial mycosis Tinea nigra. The patient received Butenafine hydrochloride 1% for 30 days, resulting in a complete remission of the lesion. At a follow-up visit 12 months after treatment, there was no lesion recurrence. We describe a form of rare geographical Tinea nigra with a speckled pattern. The "salt and pepper" aspect should be taken into consideration when the mycosis was suspected. A 7-year-old Caucasian female child, who was a resident of Itapema town on the northern coast of Santa Catarina State, Brazil, presented dark spots on the left palm about 1 month before the exam; they converged to a unique macule with speckled pattern, with a 1.5 +2.0-cm diameter and geographic shape (Figure 1). The mycological exam revealed septate, dematiaceous hyphae, and presence of yeast-like cells with spores. The fungi culture in Sabouraud's agar showed a moist, shiny, rough, and black colony. The fungi in the culture were identified as Hortaea werneckii (Figure 2). The topical treatment with Butenafine hydrochloride 1% for 4 weeks caused complete remission of lesions, with no recurrence during follow-up for 1 year.
-
Tinea nigra: successful treatment with topical Butenafine Tinea nigra: tratamento bem-sucedido com butenafina tópica
Sociedade Brasileira de Dermatologia, 2012Co-Authors: André Luiz Rossetto, Rosana Cé Bella CruzAbstract:The authors report a case of Tinea nigra in an 8-year-old child, male, from Itajaí, SC, Brazil, with lesions of the macular hyperchromic type, unique, asymptomatic, localized in the right palmar area. The lesion was treated with the topical antifungal Butenafine, with remission of symptoms and without recurrence at follow-up for two years.Os autores relatam um caso de Tinea nigra observada em criança com oito anos de idade, do sexo masculino, procedente de Itajaí, Estado de Santa Catarina, Brasil, com lesão do tipo mácula hipercrômica, única, assintomática e localizada na região palmar direita. A lesão foi tratada com o antifúngico tópico butenafina com remissão completa do quadro e sem recorrência no acompanhamento por dois anos
-
Tinea nigra: successful treatment with topical Butenafine
Anais Brasileiros de Dermatologia, 2012Co-Authors: André Luiz Rossetto, Rosana Cé Bella CruzAbstract:The authors report a case of Tinea nigra in an 8-year-old child, male, from Itajai, SC, Brazil, with lesions of the macular hyperchromic type, unique, asymptomatic, localized in the right palmar area. The lesion was treated with the topical antifungal Butenafine, with remission of symptoms and without recurrence at follow-up for two years.
